Clinical experiences with tolterodine

Life Sciences

Volumn 68, Issue 22-23, 2001, Pages 2549-2556

  Nilvebrant, Lisbeth ^a  

^a Biov Life Sci Consult c o NPC AB   (Sweden)

Author keywords

Dry mouth; Human; Selectivity; Urge incontinence; Urinary bladder

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; RECEPTOR SUBTYPE; TOLTERODINE;

ARTICLE; BLADDER; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETRUSOR DYSSYNERGIA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MICTURITION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND; URGE INCONTINENCE; XEROSTOMIA;

ANIMALIA;

EID: 0035957546     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(01)01051-7     Document Type: Conference Paper

References (20)

1. Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of the quality-of-life aspects of urinary incontinence. Pharmacoeconomics 1996;9:11-23.
2. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs & Ageing 1995;6(3):243-62.
3. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000;55 (5A, Suppl):33-46.
4. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. British Journal of Obstetrics and Gynaecology 1997;104:988-93.
5. Nilvebrant L, Hallén B, Larsson G. Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data. Life Sciences 1997;60(13/14):1129-36.
6. Nilvebrant L. The mechanism of action of tolterodine. Reviews in Contemporary Pharmacotherapy 2000;11(1):13-27.
7. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. British Journal of Pharmacology 1997; 120:1409-18.
8. Somogyi GT, de Groat WC. Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sciences 1999;64 (6/7):411-19.
9. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997;50 (6A, Suppl.):90-6.
10. Brynne N, Stahl MMS, Hallén B, Edlund PO, Palmér L, Höglund P, Gabrielsson J. Pharmacokinetics and pharmacodynamics of tolterodine in man: A new drug for the treatment of urinary bladder overactivity. International Journal of Clinical Pharmacology and Therapeutics 1997;35(7):287-95.
11. Stahl MMS, Ekström B, Sparf B, Mattiasson A, Andersson K-E. Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourology and Urodynamics 1995;14(6):647-55.
12. Larsson G, Hallén B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase II efficacy and safety data. Urology 1999;53(5):990-5.
13. Jonas U, Höfner K, Madersbacher H, Holmdahl TH-and the participants of the international study group. Efficacy and safety of two doses of tolterodine vs. placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence and urgency: Urodynamic evaluation. World Journal of Urology 1997;15: 144-51.
14. Malone-Lee JG. The efficacy, tolerability and safety profile of tolterodine in the treatment of overactive/unstable bladder. Reviews in Contemporary Pharmacotherapy 2000;11(1):29-42.
15. Chancellor M, Freedman S, Mitcheson HD, Antoci J, Primus G, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation 2000;19(2):83-91.
16. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin. Journal of the American Geriatrics Society 1998;46(1):6-13.
17. Nilvebrant L, Påhlman I, d'Argy R. Tissue distribution of tolterodine and its metabolites: Low penetration into the central nervous system. European Urology 2000;37(Suppl 2):84 (Abstract 333).
18. Dimpfel W, Todorova A, Vonderheid B. Electrophysiological evaluation of potential adverse effects of tolterodine, oxybutynin and trospium chloride on the central nervous system. Neurourology and Urodynamics 2000;19 (4):487-8 (Abstract 94).
19. Goessel C, Sauter T, Michael T, Bergé B, Staehler M, Miller K. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology 2000; 55(3):414-18.
20. Van Kerrebroeck PEVA (on behalf of the tolterodine study group). Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder. Neurourology and Urodynamics 2000; 19(4):493-4 (Abstract 89).